An experimental treatment protects mice from COVID-19, flu, bacteria, and more.

In an early animal test, a new nasal-spray vaccine has shown promise against a variety of germs and a common allergen, ...

The SWOG S1602 trial ( NCT03091660) evaluated the noninferiority of the Tokyo versus TICE BCG strains, as well as testing the superiority of T cell priming with intradermal BC before intravesical ...

Imagine if a nasal spray could make you immune not only to the viruses that cause COVID-19 and influenza, but to all respiratory diseases. In a paper 1 published in Science today, researchers describe ...

ImmunityBio's stock has roughly quintupled so far in 2026 as the company continues to deliver good news for investors.

Whether BCG strains other than BCG TICE are safe and effective for treating high-grade NMIBC warrants rigorous testing.

Prime Minister Modi launched the nationwide HPV vaccination campaign from Ajmer. Rajasthan conducted 188 vaccination sessions on the campaign's first day. Over 8.32 lakh girls in Rajasthan are ...

ImmunityBio (NASDAQ:IBRX) executives used the company’s full-year 2025 earnings call to highlight a sharp ramp in ANKTIVA ...

Q4 2025 Earnings Call March 3, 2026 4:30 PM ESTCompany ParticipantsPatrick Soon-Shiong - Founder, Executive Chairman and ...

Detailed price information for Immunitybio Inc (IBRX-Q) from The Globe and Mail including charting and trades.